Medication info
Preneu Capsule 150 mg (Pregabalin)

Preneu Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Pamgen Science Co., Ltd.
Appearance
White hard capsule containing white powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201704854 · Approved 2017.06.28 · Insurance code 670104140

Summary

Main use
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally in 2 divided doses per day, regardless of food, based on the total daily dose of pregabalin. Since this medicine is eliminated mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies were also conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose adjusted for renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: A supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescents aged 12–17 years, as sufficient safety and efficacy data are not available.

Ingredients

Manufacturer
Pamgen Science Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also administered as an adjunctive therapy for partial seizures in epilepsy patients, regardless of secondary generalization. Additionally, it is effectively used to alleviate the symptoms of fibromyalgia. In summary, it helps in the treatment of various neuropathic pain conditions, epileptic seizures, and musculoskeletal disorders.

How to take

Adult dose

This medicine is administered orally in 2 divided doses per day, regardless of food, based on the total daily dose of pregabalin. Since this medicine is eliminated mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Although clinical studies were also conducted at a dose of 600 mg/day, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose adjusted for renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: A supplemental dose refers to an additional single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescents aged 12–17 years, as sufficient safety and efficacy data are not available.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, hence careful observation for signs of depression, mood changes, or behavioral abnormalities is necessary while on treatment. Patients allergic to any ingredient of this medication should not use it. Diabetic patients may need to adjust the dosage of their blood glucose-lowering medication if weight gain occurs with this medication. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, discontinue use immediately and consult a healthcare professional. Elderly individuals are at higher risk of falling or injury due to dizziness or drowsiness, so they should exercise particular caution at the start of treatment. There may be blurred vision or changes in eyesight while taking this medication; if these symptoms occur, consult a doctor. Suddenly stopping this medication may lead to withdrawal symptoms, such as insomnia, headaches, and anxiety, so adjusting the dosage according to the physician’s instruction is necessary. Due to the risk of drug abuse, patients with a history of drug abuse or psychiatric disorders should use this medication with caution. Patients with impaired kidney function may need to adjust the dosage based on their symptoms in consultation with a healthcare professional. Patients with cardiovascular diseases may experience edema or symptoms of heart failure when taking this medication, so care is required. Caution is advised when taking this medication with opioid analgesics, as it may enhance central nervous system depressant effects, leading to risks such as respiratory distress. In early pregnancy, there is a risk of fetal malformations; hence pregnant women are advised against using this medication, and women of childbearing potential should employ effective contraception during treatment. Breastfeeding women should carefully consider the effects of this medication being transmitted through breast milk on their babies. Caution is required when driving or operating hazardous machinery as this medication may cause dizziness or drowsiness. In case of overdose, symptoms such as drowsiness, confusion, and depression may occur, and immediate medical attention is necessary. This medication should be kept out of reach of children, and transferring it to another container could lead to decreased quality or accidents.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disturbance, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, suicidal ideation, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory suppression, rhinitis, neutropenia, increased appetite, appetite loss, hypoglycemia, confusion, disorientation, irritability, euphoric feeling, decreased libido, insomnia, depersonalization, paraphilia, restlessness, anxiety, mood instability, emotional lowering, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, ataxia, motor coordination abnormalities, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech impairment, hypertonia, decreased reflexes, motor abnormality, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, tremor at rest, syncope, stupor, hypokinesia, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, ocular swelling, decreased vision, eye pain, eye fatigue, increased tear secretion, ocular irritation, mydriasis, changes in depth perception during vibration, strabismus, brightness of the visual field, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, bradycardia, paroxysmal tachycardia, arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory suppression, vomiting, abdominal distension, constipation, xerostomia, abdominal distension, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urine output, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, sensory disturbances, fatigue, tightness in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorders, drowsiness, disorientation, agitation, restlessness, exacerbation of seizures, gastrointestinal disorders, tinnitus, sleep disorders, skin diseases, increased BUN, hematochezia, colon cancer, gastritis, pneumonia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is advisable to keep it in a cool place between 15 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

White hard capsule containing white powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.